author-photo

Martin Erlanson

Umeå University

67

Papers

2182

Citations

Citation Trend

Filter By

Papers (51) Sort By

Journal Conference Others

High risk of cardiovascular side effects after treatment of Hodgkin’s lymphoma – is there a need for intervention in long-term survivors?

2021 Upsala Journal of Medical Sciences
Show All
- Source
- Cite
- Save
Citations (0)
DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma.

2020 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (2)
Epigenetic and genetic distinctions between T-cell acute lymphoblastic leukemia and lymphoma

2019
Show All
- Source
- Cite
- Save
Citations (0)
No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

2019 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (9)
Cell‐of‐origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B‐cell lymphoma

2019 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (12)
First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin’s lymphoma

2017 Bone Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (1)
LYMRIT 37-01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177 LU-LILOTOMAB SATETRAXETAN, A NOVEL CD37-TARGETED ANTIBODY- RADIONUCLIDE-CONJUGATE IN RELAPSED NHL PATIENTS

2017 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A HIGHER AMOUNT OF LILOTOMAB PRE-DOSING INCREASES THE ACTIVITY-ADJUSTED AUC AND HAS A PROTECTIVE EFFECT AGAINST MYELOSUPPRESSION OF LUTETIUM (177LU)-LILOTOMAB SATETRAXETAN IN INDOLENT NHL PATIENTS

2017 Haematologica
Show All
- Source
- Cite
- Save
Citations (2)
Abstract LB-252: Efficacy and safety results of Betalutin® (177Lu-DOTA-HH1) in a phase I/II study of patients with non-hodgkin B-cell lymphoma (NHL)

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
177lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

2016 Blood
Show All
- Source
- Cite
- Save
Citations (1)